Sanofi and GSK launch trial for COVID-19 protein-based vaccine

Sanofi and GSK said in a joint statement on Thursday they had started the "Phase 1/2" trial for their adjuvanted COVID-19 vaccine, which they hope to make available across the world.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/34Z6gBe
via IFTTT